StreetInsider.com News Articles

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Thu, 11 Jun 2026 15:03:00 -0400

Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions

CHICAGO--(BUSINESS WIRE)-- Paragon Biosciences today announced the closing of the sale of Emalex Biosciences to Teva Pharmaceutical, reinforcing Paragon's ability to build innovative biotechnology companies that deliver important treatments to the patients who need them.

Emalex is another Paragon Biosciences-founded company built to develop a novel class of treatment for patients with central nervous system disorders, following in the footsteps of other successful Paragon companies such as Harmony Biosciences (NASDAQ: HRMY). Ecopipam, an investigational compound, was developed by Emalex for

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Thu, 11 Jun 2026 15:03:00 -0400

Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Thu, 11 Jun 2026 15:03:00 -0400

Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Thu, 11 Jun 2026 15:03:00 -0400

Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Thu, 11 Jun 2026 15:03:00 -0400

Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Thu, 11 Jun 2026 15:03:00 -0400

Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Thu, 11 Jun 2026 15:03:00 -0400

Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions

Paragon Advances Registration-Ready CNS Asset Addressing Important Unmet Need and Closes Sale to Teva Pharmaceutical

Thu, 11 Jun 2026 15:03:00 -0400

Agreement highlights Paragon’s ability to build companies around important science, advance registration-ready assets, and deliver value through strategic transactions

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Thu, 11 Jun 2026 08:05:00 -0400

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that six abstracts in narcolepsy and idiopathic hypersomnia have been accepted for poster presentation at SLEEP 2026, the 40th annual meeting of the Associated Professional Sleep Societies (APSS), which will be held June 14 – 17 in Baltimore, MD.

The poster presentation details are as follows:

Abstract Title

Poster Presentation Session

Treatment with Pitolisant in Subgroups

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Thu, 11 Jun 2026 08:05:00 -0400

The poster presentation details are as follows:

Abstract Title

Poster Presentation Session

Treatment with Pitolisant in Subgroups

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Thu, 11 Jun 2026 08:05:00 -0400

The poster presentation details are as follows:

Abstract Title

Poster Presentation Session

Treatment with Pitolisant in Subgroups

Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting

Thu, 11 Jun 2026 08:05:00 -0400

The poster presentation details are as follows:

Abstract Title

Poster Presentation Session

Treatment with Pitolisant in Subgroups

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Tue, 09 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260609/26624103.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Tue, 09 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260609/26624103.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Fri, 05 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260605/26611180.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Fri, 05 Jun 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260605/26611180.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Thu, 04 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260604/26606053.html

Form 144 Harmony Biosciences Hold Filed by: Kapadia Sandip

Thu, 04 Jun 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260604/26606053.html

Harmony Biosciences to Participate in Upcoming Investor Conferences

Wed, 27 May 2026 08:05:00 -0400

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in the following upcoming investor conferences.

Goldman Sachs 47th Annual Global Healthcare Conference

Fireside Chat: June 9, 2026, at 8:40 a.m. ET
Location: Miami, FL

Oppenheimer CNS & Neuro-Muscular Summit

Fireside Chat: June 10, 2026, at 3:25 p.m. ET
Location: Miami, FL

A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare

Harmony Biosciences to Participate in Upcoming Investor Conferences

Wed, 27 May 2026 08:05:00 -0400

Goldman Sachs 47th Annual Global Healthcare Conference

Fireside Chat: June 9, 2026, at 8:40 a.m. ET
Location: Miami, FL

Oppenheimer CNS & Neuro-Muscular Summit

Fireside Chat: June 10, 2026, at 3:25 p.m. ET
Location: Miami, FL

A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare

Harmony Biosciences to Participate in Upcoming Investor Conferences

Wed, 27 May 2026 08:05:00 -0400

Goldman Sachs 47th Annual Global Healthcare Conference

Fireside Chat: June 9, 2026, at 8:40 a.m. ET
Location: Miami, FL

Oppenheimer CNS & Neuro-Muscular Summit

Fireside Chat: June 10, 2026, at 3:25 p.m. ET
Location: Miami, FL

A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare

Harmony Biosciences to Participate in Upcoming Investor Conferences

Wed, 27 May 2026 08:05:00 -0400

Goldman Sachs 47th Annual Global Healthcare Conference

Fireside Chat: June 9, 2026, at 8:40 a.m. ET
Location: Miami, FL

Oppenheimer CNS & Neuro-Muscular Summit

Fireside Chat: June 10, 2026, at 3:25 p.m. ET
Location: Miami, FL

A webcast of the fireside chats will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.

About Harmony Biosciences

Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare

H.C. Wainwright Reiterates Buy Rating on Harmony Biosciences Holdings Inc. (HRMY)

Fri, 22 May 2026 06:52:25 -0400

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating and $55.00 price target on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY).

The analyst commented: "On May 7, Harmony reported 1Q26 net product revenue of $215.4 million (a touch below our $218.8 million estimate, and below the $221 million FactSet consensus as of May 1), and GAAP EPS of $0.55 (below our $0.76 estimate and the $0.69 consensus), with the EPS shortfall primarily driven by $32 million in upfront licensing expenses tied to the Novitium amorphous pitolisant license, which had an after-tax impact of $0.45/share. WAKIX revenue increased 17% year-over-year (YoY) despite more

Form 3 Harmony Biosciences Hold For: May 14 Filed by: Germano Geno J

Mon, 18 May 2026 21:51:00 -0400

si-local-file:///var/storage/secattach/20260518/26515789.html

Form 3 Harmony Biosciences Hold For: May 14 Filed by: Germano Geno J

Mon, 18 May 2026 21:51:00 -0400

si-local-file:///var/storage/secattach/20260518/26515789.html